[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100289855":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":10,"locations":16,"responsibleParty":83,"collaborators":10,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":10,"studyType":100,"phases":10,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":114,"whyStopped":10,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Paritaprevir\u002FRitonavir + Ombitasvir + Dasabuvir",null,"Participants with chronic hepatitis C (CHC) genotype 1b (GT1b) and compensated liver cirrhosis received paritaprevir\u002Fritonavir (r), ombitasvir and dasabuvir (3DAA ABBVIE REGIMEN) for 12 weeks.\n\nThe prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer a patient the opportunity to participate in this study.",[13],{"name":14,"affiliation":5,"role":15},"AbbVie Inc.","STUDY_DIRECTOR",[17,29,38,47,56,65,74],{"facility":18,"status":10,"city":19,"state":10,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":10},"South-Ural State Med. Academy","Chelyabinsk","454052","Russia","RU",{"type":24,"coordinates":25},"Point",[26,27],61.42877,55.1611,{"lat":27,"lon":26},{"facility":30,"status":10,"city":31,"state":10,"zip":32,"country":21,"countryCode":22,"cosmosGeoPoint":33,"geoPoint":37,"contacts":10},"KOGBUZ Kirovsk Infect Hosp","Kirov","610008",{"type":24,"coordinates":34},[35,36],49.65783,58.59809,{"lat":36,"lon":35},{"facility":39,"status":10,"city":40,"state":10,"zip":41,"country":21,"countryCode":22,"cosmosGeoPoint":42,"geoPoint":46,"contacts":10},"Specialized Clinical Infectiou","Krasnodar","350000",{"type":24,"coordinates":43},[44,45],38.98178,45.04534,{"lat":45,"lon":44},{"facility":48,"status":10,"city":49,"state":10,"zip":50,"country":21,"countryCode":22,"cosmosGeoPoint":51,"geoPoint":55,"contacts":10},"Orenburg Regional Clinical Hos","Orenburg","460018",{"type":24,"coordinates":52},[53,54],55.09883,51.76712,{"lat":54,"lon":53},{"facility":57,"status":10,"city":58,"state":10,"zip":59,"country":21,"countryCode":22,"cosmosGeoPoint":60,"geoPoint":64,"contacts":10},"LLC Medical Company","Samara","443063",{"type":24,"coordinates":61},[62,63],50.13553,53.20767,{"lat":63,"lon":62},{"facility":66,"status":10,"city":67,"state":10,"zip":68,"country":21,"countryCode":22,"cosmosGeoPoint":69,"geoPoint":73,"contacts":10},"GBOU VPO Saratov state Med Uni","Saratov","410012",{"type":24,"coordinates":70},[71,72],45.9901,51.54048,{"lat":72,"lon":71},{"facility":75,"status":10,"city":76,"state":10,"zip":77,"country":21,"countryCode":22,"cosmosGeoPoint":78,"geoPoint":82,"contacts":10},"Ulyanovsk Regional Clin Hosp","Ulyanovsk","432018",{"type":24,"coordinates":79},[80,81],48.38657,54.32824,{"lat":81,"lon":80},{"type":84,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100289855","real-world-evidence-of-the-effectiveness-of-paritaprevirritonavir-r---ombitasvir--dasabuvir-without-ribavirin-in-participants-with-chronic-hepatitis-c-and-compensated-liver-cirrhosis-in-the-russian-federation-100289855",true,"NCT03053180","Real World Evidence of the Effectiveness of Paritaprevir\u002FRitonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation","Real World Evidence Study of the Effectiveness of Paritaprevir\u002Fr - Ombitasvir, + Dasabuvir Without Ribavirin in Patients With Chronic HCV Gt1b Infection and Compensated Liver Cirrhosis in the RussIan FederaTion- An ObseRvational, MultI-CeNter Study (CITRIN)","CITRIN","Inclusion Criteria:\n\n* 3DAA ABBVIE REGIMEN will be prescribed by physicians according to the routine clinical practice\n* Treatment-naïve or interferon (IFN)\u002Fribavirin (RBV)-experienced participants with confirmed CHC Gt1b and compensated liver cirrhosis, receiving therapy with the interferon-free 3DAA ABBVIE REGIMEN initiated not earlier than 2 weeks before the enrollment or the initiation is planned not later than 2 weeks after the day of enrollment in accordance to standard of care and in line with the current local label\n* Participants must not be participating or intending to participate in a concurrent interventional therapeutic trial\n\nExclusion Criteria:\n\n* Co-administration ribavirin (RBV) with the 3DAA ABBVIE REGIMEN\n* Participants with Child Pugh B and C cirrhosis\n* Participants with a history of prior direct-acting antiviral agent (DAA) therapy\n* Any other contraindications to the administration of 3DAA ABBVIE REGIMEN according to the label",false,"ALL","18 Years","99 Years",{"count":98,"type":99},60,"ACTUAL","OBSERVATIONAL","This prospective, multi-center, observational study is designed to assess the real world effectiveness of paritaprevir\u002Fr - ombitasvir with dasabuvir (3DAA \\[direct-acting antiviral agent\\] ABBVIE REGIMEN) without ribavirin (RBV) and to describe baseline characteristics of participants with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection and compensated liver cirrhosis in Russia.",[103],"Chronic Hepatitis C",[105,106,107,108,109,110,111,112,113],"Paritaprevir","Dasabuvir","Ombitasvir","Ritonavir","Ribavirin free","Chronic Hepatitis C genotype 1b (GT1b)","Cirrhosis","Compensated liver cirrhosis","Hepatitis","COMPLETED","2018-11-20",{"date":117,"type":99},"2019-03-14",{"date":119,"type":99},"2017-03-20",{"date":121,"type":99},"2017-12-18",{"name":5,"class":6},7]